### 505785316 11/21/2019

### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5832144

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
CELLTECH R&D LIMITED	05/22/2018

### **RECEIVING PARTY DATA**

Name:	UCB BIOPHARMA SPRL	
Street Address:	ALLEE DE LA RECHERCHE, 60	
City:	BRUSSELS	
State/Country:	BELGIUM	
Postal Code:	B-1070	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16615419

### **CORRESPONDENCE DATA**

**Fax Number:** (352)372-5800

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 3523758100

Email: fce@slepatents.com

**Correspondent Name:** FRANK C. EISENSCHENK, PH.D.

Address Line 1: P.O. BOX 142950

Address Line 4: GAINESVILLE, FLORIDA 32614-2950

ATTORNEY DOCKET NUMBER:	UCB.133	
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.	
SIGNATURE:	/FRANK C. EISENSCHENK/	
DATE SIGNED:	11/21/2019	

### **Total Attachments: 7**

source=exec-Asgn-Celltech2Bioph#page1.tif source=exec-Asgn-Celltech2Bioph#page2.tif source=exec-Asgn-Celltech2Bioph#page3.tif source=exec-Asgn-Celltech2Bioph#page4.tif source=exec-Asgn-Celltech2Bioph#page5.tif source=exec-Asgn-Celltech2Bioph#page6.tif

> PATENT REEL: 051075 FRAME: 0899

505785316

source=exec-Asgn-Celltech2Bioph#page7.tif

PATENT REEL: 051075 FRAME: 0900

# CONFIRMATORY ACKNOWLEDGEMENT, ASSIGNMENT AND UNDERTAKING AGREEMENT

THIS AGREEMENT is made the \_\_\_\_\_\_\_ day of \_\_\_\_\_\_\_ May \_\_\_\_\_ between

(1) Gill RENNER
C/O Intellectual Property Dept
UCB Celltech
208 Bath Road
Slough
Berkshire, SL1 3WE
UNITED KINGDOM

("THE INVENTOR");

(2) CELLTECH R&D Limited 208 Bath Road

208 Bath Road Slough Berkshire SL1 3WE UNITED KINGDOM ("UCB CELLTECH")

(3) UCB BIOPHARMA SPRL Allée de la Recherche, 60 B-1070 Brussels BELGIUM ("UCB BIOPHARMA")

### WHEREAS

- (A) The Inventor has been determined as being the sole inventor or one of the joint inventors of the invention or inventions entitled " Cell Culture Methods" and identified by the patent family reference number PF0104 ("the Invention")
- (B) At the time the Invention was made, the Inventor was employed by UCB CELLTECH;
- (C) The Invention is described in a patent application ("the Application"), identified by the following short particulars, which patent application has with the consent of all the parties hereto been filed in the name of **UCB BIOPHARMA** with the patent office shown:

Patent Office	Filing Date	Application Number
UK Patent Office	31 May 2017	1708655.4

- (D) It is the wish and intention of all the parties hereto that:
  - (i) the Application shall continue in the name of UCB BIOPHARMA;
  - (ii) any patent application or like application filed in any country or territory and being directed to the Invention (whether or not claiming priority under the Paris Convention or like arrangement from the Application and including all divisional

1/7

applications, applications for patents of addition, continuation applications, continuation-in-part applications, applications for re-issue national applications, patent term extensions, supplementary protection certificates, regional applications and international applications and like corresponding applications) ("Corresponding Application(s)") shall be in the name of and shall vest in UCB BIOPHARMA; and

(iii) any patent granted on the Application or on any Corresponding Application(s) shall be in the name of and shall vest in **UCB BIOPHARMA**.

## NOW THIS AGREEMENT WITNESSETH:

- THE INVENTOR ACKNOWLEDGES that:
  - a) he or she made the Invention as part of his or her normal duties as employee of **UCB CELLTECH** and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his or her duties; and
  - b) all his or her right, title, and interest in the invention transferred to UCB CELLTECH by virtue of applicable Law.
- 2. All right, title and interest in the Invention have transferred from UCB CELLTECH to UCB BIOPHARMA by virtue of a series of intercompany agreements which have entered into force prior to the filing date of the Application.

  UCB CELLTECH hereby agrees that UCB BIOPHARMA has and shall have the exclusive rights to the Invention and all patent applications and resulting patents pertaining to the Invention, as well as the exclusive right to apply for patents, or any other such protection of intellectual property rights for the Invention, including for the avoidance of doubt the Application and the Corresponding Application(s).
- 3. UCB CELLTECH and THE INVENTOR ACKNOWLEDGE that all right, title and interest in the Invention thereof are vested in UCB BIOPHARMA and that UCB BIOPHARMA has the exclusive rights to:
  - (i) the Invention;
  - the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
  - (iii) recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any

Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

# TO HOLD unto UCB BIOPHARMA absolutely.

- 4. Insofar as the rights in the Invention and the Application are still vested in THE INVENTOR and/or UCB CELLTECH and, in consideration of One Dollar (\$1.00) and other good and valuable consideration in hand paid, the receipt and sufficiency whereof are hereby acknowledged, THE INVENTOR and/or UCB CELLTECH, HEREBY ASSIGNS to UCB BIOPHARMA:
  - (i) the Invention;
  - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
  - (iii) the right to recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

# TO HOLD unto UCB BIOPHARMA absolutely.

- UCB BIOPHARMA HEREBY ACCEPTS all that is transferred to it under this Agreement.
- 6. EACH OF THE INVENTOR AND UCB CELLTECH HEREBY UNDERTAKES to do or have done as and when required by UCB BIOPHARMA, or its nominee as UCB BIOPHARMA shall direct, and at the expense of UCB BIOPHARMA, any and all acts and things including the execution of documents necessary or expedient for perfecting the assignments contained herein and/or for giving effect to the wishes and intentions of the parties hereto.
- 7. EACH OF THE INVENTOR AND UCB CELLTECH HEREBY AUTHORISES UCB BIOPHARMA or its nominee and the agents of any of them as UCB BIOPHARMA shall direct to insert here below at (\*) the relevant application number and/or any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document:

(*) US Serial No :	16/615,419
and/or PCT Application No : Filing Date :	November 21, 2019

- 8. IN THE EVENT THAT ANY OF THE TERMS OF THIS AGREEMENT is held to be invalid, the remainder of the terms shall continue in full force and effect.
- THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with law governing Prior Agreement.

IN WITNESS whereof the parties have caused this agreement to be duly executed on the day and year first above written.

This page remains without signatures on purpose – all signatures are executed on follow-up pages (5-7).

## Signed by THE INVENTOR

GIII RENNER

Signature:

Place:

SLOUGH

Witness signature:

Name:

Address:

Place:

SARAM MUMPHROYS

Address:

SLOUGH

Witness signature:

SARAM MUMPHROYS

Address:

Place:

SLOUGH, UK

Address:

Address:

SLOUGH, UK

Place:

SLOUGH, UK

SLOUGH, UK

SLOUGH, UK

SLOUGH, UK

SLOUGH, UK

Place:

SLOUGH, UK

SLOUGH, UK

SLOUGH, UK

Signed for and on behalf of OCB CELETEON		
By: Name: Title:	Yogesh KHATRI Pinance Director	
Signature:	Yearlingh, UK	
Witness signature:	SIL, ALARIE	
Name:	SARAH FULMPH 12015	
Address:	90 208 Sapri Regict	
Place:	SLOMAY, UC	
Witness signature:	hASeologheor	
Name:	KATE SEKGREER	
Address:	do 208 Bath Kead	
Place:	SLOW OH, ML	

Signed for and on	hehalf of I	JCB B	IOPHARMA
-------------------	-------------	-------	----------

Ву:

Name: Stéphane DROUIN

Title: Vice President, Head Stroup Intellectual Property

Signature:

Place:

Witness signature:

Name:

Marina CRAINICH

Address:

UCB Biopharma SPRL Allée de la Recherche, 60

Place:

B-1070 Bruxelles - Belgium

Witness signature:

Name:

· CHANGE DENGARIO

Address:

UCB Biopharma SPELL. Allée de la Recherche, 60

Place:

B-1070 Bruxelles - Beloi-